Momelotinib
Published
Unassigned
New Medicines
Myelofibrosis
Information
New molecular entity
Sierra Oncology
Sierra Oncology
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2)
The UK incidence of MF is 0.5-1.5 per 100,000 people. The median age at diagnosis is 60 years, and more than 90% of patients are diagnosed after age 40 years. However myelofibrosis has been reported in all age groups. Overall median survival is 5 years.
Myelofibrosis
Oral